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A new pathogenic candidate for diabetic macular edema
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OBJECTIVEdHemopexin is a well-recognized permeability factor in the kidney, but its po-
tential role in blood-retinal barrier (BRB) breakdown has not been explored. The main aims of
this study were as follows: 1) to determine hemopexin expression in the retina and its content in
the vitreous fluid from diabetic patients with diabetic macular edema (DME) and nondiabetic
patients, 2) to evaluate the effect of hemopexin on BRB permeability, and 3) to determine whether
dexamethasone prevents an eventual hemopexin-induced hyperpermeability.
RESEARCHDESIGNANDMETHODSdBiological material included 1) retinas from 10
diabetic donors with nonproliferative retinopathy and from 10 nondiabetic donors and 2) vit-
reous fluid from 14 patients with DME and 14 nondiabetic patients. Hemopexin and hemopexin
receptor mRNA levels were measured by quantitative RT-PCR and hemopexin concentrations by
ELISA. The effect of hemopexin on permeability in culture was evaluated in human retinal
pigment epithelial (ARPE)-19 cells and bovine retinal endothelial cells. The experiments were
repeated in the presence of hemopexin-neutralizing antibodies and dexamethasone.
RESULTSdA higher expression of hemopexin was detected in the retinal pigment epithelium
(RPE) from diabetic patients in comparison with nondiabetic control subjects. Intravitreal hemo-
pexin concentration was higher in patients with DME than in nondiabetic subjects. Hemopexin
significantly increased permeability in ARPE-19 cells, which was prevented by both hemopexin-
neutralizing antibodies and dexamethasone.
CONCLUSIONSdHemopexin is overexpressed in the RPE of diabetic patients with DME
and induces the breakdown of RPE cells in vitro. Dexamethasonewas able to prevent hemopexin-
induced hyperpermeability. Our results suggest that hemopexin can be considered a new path-
ogenic candidate for DME.
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D iabetic retinopathy remains theleading cause of preventable blind-ness among working-age individu-
als in developed countries (1). Whereas
proliferative diabetic retinopathy (PDR)
is the commonest sight-threatening lesion
in type 1 diabetes, diabetic macular
edema (DME) is the primary cause of
poor visual acuity in type 2 diabetes. Be-
cause of the high prevalence of type 2 di-
abetes, DME is the main cause of visual
impairment in diabetic patients (2).
When clinically significant DME appears,
laser photocoagulation is currently
indicated. However, the optimal period
of laser treatment is frequently passed
and, moreover, is not uniformly success-
ful in halting visual decline. In addition,
photocoagulation is not without side ef-
fects, with visual field loss and impair-
ment of either adaptation or color vision
being the most frequent. Intravitreal cor-
ticosteroids have been successfully used
in eyes with persistent DME and loss of
vision after the failure of conventional
treatment. However, reinjections are
commonly needed, and there are substan-
tial adverse effects such as infection,
glaucoma, and cataract formation. Intra-
vitreal anti–vascular endothelial growth
factor (VEGF) agents have also found an
improvement of visual acuity and de-
crease of retinal thickness in DME, even
in nonresponders to conventional treat-
ment (3). However, apart from local side
effects such as endophthalmitis and reti-
nal detachment, the response to treat-
ment of DME by VEGF blockade is not
prolonged and is subject to significant
variability. For all these reasons, new
pharmacological treatments based on
the understanding of the pathophysiolog-
ical mechanisms of DME are needed.
Vascular leakage due to the break-
down of the blood-retinal barrier (BRB) is
the main event involved in the pathogen-
esis of DME (4). However, little is known
regarding the molecules primarily in-
volved in this event. By means of a pro-
teomic analysis, we have found that
hemopexin was significantly increased
in the vitreous fluid of patients with
DME in comparison with PDR and non-
diabetic control subjects (5). Hemopexin
is the best characterized permeability fac-
tor in steroid-sensitive nephrotic syn-
drome (6,7). In addition, hemopexin
could be involved in either causing or per-
petuating enhanced glomerular perme-
ability in minimal change nephrotic
syndrome (7). T cell–associated cytokines
like tumor necrosis factor-a are able to
enhance hemopexin production in me-
sangial cells in vitro, and this effect is pre-
vented by corticosteroids (8). However,
whether hemopexin also acts as a perme-
ability factor in the BRB and its potential
response to corticosteroids remains to be
elucidated.
On these bases, the aims of the cur-
rent study were 1) to compare hemopexin
and hemopexin receptor (LDL receptor–
related protein [LRP1]) levels in retina
and in vitreous fluid from diabetic and
nondiabetic patients, 2) to evaluate the
effect of hemopexin on the permeability
of outer and inner BRB in cell cultures, and
3) to determine whether anti-hemopexin
antibodies and dexamethasone were able
to prevent an eventual hemopexin-induced
hyperpermeability.
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Ten human postmortem eyes were ob-
tained from diabetic donors (age 66.9 6
5.4 years) with nonproliferative diabetic
retinopathy (NPDR). Ten eye cups ob-
tained from nondiabetic donors matched
by age (age 67.2 6 6.8 years) were used
as the control group. The time elapsed
from death to eye enucleation was ,4 h.
After enucleation, one eye of each donor
was snap-frozen at –808C and stored un-
til assayed for mRNA and Western blot
analyses.
Human vitreous fluid
Samples of vitreous from 14 diabetic
patients with DME without PDR, 10 di-
abetic patients with PDR without DME,
and 14 nondiabetic subjects with idio-
pathic macular hole were selected from
our vitreous bank. Subjects with macular
hole were considered control subjects. All
groups were closely matched by age. The
exclusion criteria were 1) previous vitre-
oretinal surgery, 2) photocoagulation in
the preceding 6 months, 3) recent vitre-
ous hemorrhage (,3 months before vit-
rectomy) or intravitreous hemoglobin.5
mg/mL, 4) renal failure (creatinine $120
mmol/L), and 5) other chronic diseases
apart from diabetes.
For diabetic retinopathy classifica-
tion, we used the International Clinical
Diabetic Retinopathy Severity Scale (9).
The main characteristics of control sub-
jects and patients with DME are summa-
rized in Table 1. Details of vitrectomy and
sample collection have previously been
described elsewhere (10).
All ocular tissues were used in accor-
dance with applicable laws and with the
Declaration of Helsinki for research in-
volving human tissue. In addition, this
study was approved by the ethics com-
mittee of our hospital.
Assessment of hemopexin and its
receptor in retina
mRNA isolation and cDNA synthesis.
Neuroretina and retinal pigment epithe-
lium (RPE) were harvested under the
microscopic dissection of isolated eye
cups from donors. The neuroretina and
RPE from each eye were ground to pow-
der in liquid nitrogen using a mortar.
Tissue was homogenized by QIAshredder
spin column (Quiagen, Hilden, Ger-
many), and mRNA was extracted from
tissue using RNeasy Micro Kit (Quiagen)
according to the manufacturer’s instruc-
tions. mRNA concentration and integrity
was determined by RNA nano Laboratory
Chip kit Bioanalyzer (Agilent, Palo Alto,
CA). One microgram of total mRNA was
reverse transcribed using TaqMan Re-
verse Transcription Reagents (Applied Bio-
systems, Roche, NJ) following the
manufacturer’s protocol for random hex-
anucleotide priming.
Quantitative RT real-time PCR. Quan-
titative real-time PCR was performed
using an ABI Prism 7000 Sequence De-
tection System (Perkin-Elmer Applied
Biosystems, Madrid, Spain) according to
the manufacturer’s protocol. Levels of he-
mopexin and LRP1 were assessed with
the TaqMan Assays Hs00167197_m1
and Hs00233856_m1 (for HPX and
LRP1 detection, respectively; Applied
Biosystems). The 22DDCt method was
used to estimate relative transcript levels
with ACTB (Hs9999903_m1) as endog-
enous control. Relative quantification
data were obtained with ABI Prism
7000 SDS software (Applied Bio-
systems). Each sample was studied in
triplicate.
Measurement of hemopexin in
vitreous fluid
Hemopexin was determined by using
ELISA kit assay (Assaypro, Winfield,
MO). The vitreous was diluted 1:5 in
assay dilution buffer. The detection limit
of the assay was 50 ng/mL. Intra-assay
and interassay coefficients of variation
were 4.9 and 7.3%, respectively.
Cell cultures
In vitro model of outer BRB: human
RPE cell cultures. Human RPE (ARPE)-
19 cells (American Type Culture Collec-
tion, Manassas, VA), a spontaneously
human immortalized cell line from
RPE, was used in the experiments. Cell
cultures were maintained in 75 cm2 cell
flasks with DMEN Ham’s F-12 standard
medium supplemented with 10% FBS
(fetal bovine serum; Hyclone, Cultek,
Barcelona, Spain) and antibiotics strep-
tomycin (100 mg/mL) and penicillin
(100 units/mL) (Invitrogen, Madrid,
Spain) at 378C and 5%CO2. The concen-
tration of D-glucose in the medium was
adjusted to 25 mmol/L to mimic the dia-
betic milieu. The medium was replaced
every 3 days.
In vitro model of inner BRB: bovine
retinal endothelial cells. Bovine retinal
endothelial cells (BRECs) were isolated
frombovine eyes according to the Antonetti
andWolpert protocol (11). Briefly, retinas
isolated from bovine eyeballs from a local
farm were digested with collagenase,
DNase, and pronase at 378C for 30 min
and filtered. Endothelial cells were plated
in fibronectin (5 mg/mL; Sigma, Madrid,
Spain) and grown until confluence in
DMEN (PAA, Pasching, Austria) supple-
mented with 10% FBS serum (SBF;
Hyclone, Cultek) and the antibiotics
streptomycin (100 mg/mL) and penicillin
(100 units/mL) (Invitrogen), ECGS (20
mg/mL; Sigma, Madrid, Spain), and hep-
arin (100 mg/mL; Sigma).
Immunohistochemical analysis
Monolayers of ARPE-19 cells grown for
15 days at confluence on glass cover-
slips (Thermo Scientific; Menzel-Glaser,
Braunschweig, Germany) were subject to
appropriate treatments with plasmatic
hemopexin (50 mg/mL; Sigma) or anti-
bodies as described below. Then, cells
were washed with PBS and fixed with
cold methanol (2208C) for 10 min. After
blocking and permeabilization with PBS,
2% BSA, and 0.05% Tween overnight at
48C, monolayers were incubated with a
mouse anti-human ZO-1 primary anti-
body (diluted 1: 200; Zymed Laborato-
ries, San Francisco, CA). After washing
with PBS, monolayers were further incu-
bated with the secondary antibody Alexa
594 anti-mouse (1:200; Invitrogen, San
Diego, CA) for 1 h at room temperature.
Table 1dMain clinical features and intravitreal hemopexin concentrations of subjects
included in the study
DME PDR Control subjects P
n 14 10 14
Age (years) 60 6 9 59 6 9 61 6 12 NS
Sex (male/female) 7/7 5/5 8/6 NS
Diabetes duration (years) 11 6 5 13 6 7 d NS
A1C* (%) 8.4 6 1.9 8.2 6 0.9 d NS
Hemopexin (mg/mg) 2.98 6 0.49†# 1.59 6 1.58# 2.06 6 0.79† 0.03†, 0.02#
*Glycated hemoglobin. †P = 0.03. #P = 0.02.
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The slides were mounted with a mount-
ing medium containing DAPI for fluores-
cence (Vectashiedl; Vector Laboratories,
Burlingame, CA). Images were acquired
with a FV1000 (Olympus, Hamburg,
Germany) confocal laser microscope
with a 360 immersion objective.
Permeability studies
Outer BRB. The permeability studies
were performed following the methods
previously described by our group (12).
In summary, ARPE-19 cells were planted
at a density of 400,000 cells/mL (80,000
RPE cells/well) into polystyerene inserts
with a surface area of 0.33 cm2 (HTS-
Transwells; Corning, Corning, NY). At
this density, the cells formed a monolayer
that was maintained in culture for 15
days, with the medium being changed ev-
ery 3 days. On the 15th day, the medium
of the apical part of the insert was
replaced by deprived medium (1% SBF).
Then, plasmatic hemopexin (50 mg/mL;
Sigma) was included in the apical com-
partment. After 15 h, 70 kDa-FITC dex-
tran (100mg/mL; Sigma) was added to the
apical compartment of the insert. Ali-
quots of 200mLwere taken from the basal
compartment every 30 min and fluores-
cence read in a SpectraMax Gemini (Mo-
lecular Devices, Sunnyvale, CA) at a
wavelength of excitation/emission 485/528
nm. Finally, the concentration of dextran
was determined by extrapolation of the
fluorescence read in a standard curve.
Each condition was tested in quadrupli-
cate, and the experiments were repeated
three times.
Inner BRB. For BREC cell permeability
studies, cells were seeded in endothelial
complete medium into transwells (HTS-
Transwells; Costar; Corning) (100,000
cells/insert). Cells were maintained in
monolayer for 7 days before treatments.
Then, the apical compartment was de-
prived and treatments and procedures
were performed as described above.
Neutralization assay
Hemopexin solution (50mg/mL) was pre-
pared in a deprived medium (1% SBF).
Then, the required concentration of anti-
body was added to the solution and the
tubs were briefly mixed by vortexing and
incubated 1 h at 378C. Finally, the differ-
ent solutions were added to the cell mono-
layers. Three different anti-hemopexin
antibodies obtained in goat, rabbit, and
mouse (17D, 300 H, and ABS 013, respec-
tively; Santa Cruz Biotechnology, Heidel-
berg, Germany) were used. The antibody
17D is directed against the NH2-terminal
epitope of the protein, while 300 H is ob-
tained against the COOH-terminal epitope
region.
The effect of dexamethasone on
hemopexin-induced RPE cell permeability
was evaluated. ARPE-19 cells were treated
with dexamethasone (1 mmol/L) 18 h be-
fore hemopexin treatment.
Cell counting and citotoxicity
Nuclei from seven fields of each condition
were counted to determine the total num-
ber of cells and cells in division per field.
Images, equivalent to an area of 0.57
mm2, were acquired at 320 with a fluo-
rescence microscope (BX61; Olympus).
Lactate dehydrogenase (LDH) was
measured as an indicator of cell death by
using a cytotoxicity detection kit (Roche;
Applied Science, Barcelona, Spain). LDH
activity was measured in a 96-well plate
with two replicates for each condition at
an absorbance of 490 nm. Results are
expressed as percentage of cells showing
cytotoxicity 6 SD. Percent cytotoxicity =
(experimental value2 low control)/(high
control 2 low control) 3 100.
Statistical analysis
The Kolmogorov-Smirnov test was used
to confirm the assumption of the normal-
ity of the variables. A Student t test was
used to compare continuous variables
that were expressed as mean6 SD. Levels
of statistical significance were set at P ,
0.05.
RESULTS
Hemopexin and LRP1 expression in
the human retina
No differences were observed in b-actin
mRNA expression between diabetic and
Figure 1dA: Real-time quantitative RT-PCR analysis of hemopexin in RPE and neuroretina
(NR) from diabetic donors and nondiabetic donors. B: Real-time quantitative RT-PCR analysis of
LRP1 in RPE and neuroretina from diabetic donors and nondiabetic donors. Hemopexin and LRP1
gene expression data (DDCt) were calculated after normalizing by b-actin. Results are presented
as means 6 SD.
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nondiabetic retinas (P = not significant).
Thus, we have calculated hemopexin
mRNA gene expression after normalizing
with b-actin.
Significantly higher hemopexin
mRNA expression was observed in RPE
than in the neuroretina in both diabetic
(0.85 6 0.20 vs. 0.46 6 0.16; P , 0.01)
and nondiabetic (0.596 0.11 vs. 0.406
0.06; P, 0.05) donors. A higher expres-
sion of hemopexinmRNAwas detected in
the RPE from diabetic donors compared
with nondiabetic donors (P , 0.05). No
differences were observed in hemopexin
expression in neuroretina between the
two groups (Fig. 1A).
A significantly higher level of mRNA
LRP1 was observed in the RPE than in the
neuroretina in both diabetic (0.836 0.47
vs. 0.28 6 0.07; P , 0.05) and nondia-
betic (0.89 6 0.26 vs. 0.30 6 0.05; P ,
0.01) donors. However, we did not find
any difference between LRP1 mRNA lev-
els in diabetic and nondiabetic donors
in either the RPE or the neuroretina
(Fig. 1B).
Hemopexin concentration in vitreous
fluid
Intravitreous levels of hemopexin were
significantly higher in the vitreous fluid
obtained from patients with DME with-
out PDR than from with PDR without
DME and from nondiabetic subjects
(Table 1).
Effect of hemopexin on permeability
of BRB
Hemopexin treatment (50 mg/mL) does
not increase permeability in BREC. By
contrast, hemopexin produced a clear
disruption of the ARPE-19 cell mono-
layer, thus leading to a significant in-
crease of dextran permeability (75 6 8
vs. 43 6 6 ng/mL/cm2; P , 0.05). It is
worth mentioning that this effect was
detected using a hemopexin dosage
in the range detected in the vitreous
fluid of diabetic patients with DME. Pre-
treatment with anti-hemopexin anti-
bodies prevented the breakdown of the
monolayer and the increase of perme-
ability induced by hemopexin (Fig.
2A). The results of the immunohisto-
chemistry of ZO-1 performed under
the different conditions are shown in
Fig. 2B.
In order to rule out a potential bias in
the results due to changes in cell pro-
liferation, the total number of cells as
well as cells in division was counted, and
no significant differences were found
between the different conditions. In ad-
dition, we did not observe any significant
differences regarding cytotoxicity as mea-
sured by LDH assay.
Dexamethasone prevents hemopexin-
induced RPE cell hypermeability
The effect of dexamethasone on hemopexin-
induced RPE cell permeability is represented
in Fig. 3. Dexamethasone (1 mmol/L)
prevented the disruption of the ARPE-19
cellmonolayer and significantly reduced the
hyperpermeability induced by hemopexin
(P, 0.05).
CONCLUSIONSdIn the current
study, we have confirmed our previous
results obtained by a proteomic approach
Figure 2dA: Results of 70 kDa dextran permeability in ARPE-19 cells cultured under 25 mmol/L
D-glucose in the different conditions examined. The vertical axis is the concentration of dextran.
Dextran permeability was measured at 3 and 90 min. Empty bars, control condition (25 mmol/L
D-glucose); black bars, hemopexin (50 mg/mL); gray bars, hemopexin after anti-hemopexin an-
tibody (0.75mg/mL) obtained from goat; stripped bars, hemopexin after anti-hemopexin antibody
(0.75 mg/mL) obtained from rabbit; dotted bars, hemopexin after anti-hemopexin antibody (0.75
mg/mL) obtained from mouse. Results are expressed as means; n = 4. *P , 0.05 in comparison
with hemopexin treatment. B: Immunofluorescence images obtained by confocal microscopy
showing the ARPE-19 monolayer. B1: Immunostaining for ZO-1 (red) in cells cultured under
25 mmol/L D-glucose showing a well-structured monolayer. B2: Disorganization of ZO-1 and
breakdown of ARPE-19 monolayer induced by hemopexin. B3–B5: Prevention of the disruption of
ARPE-19 monolayer with anti-hemopexin antibodies before hemopexin treatment. Nuclei stained
with DAPI (blue). Bar: 10 mm. FITC, fluorescein isothiocyanate.
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showing that hemopexin is higher in the
vitreous fluid of diabetic patients with
DME in comparison with diabetic pa-
tients with PDR and nondiabetic subjects.
In addition, we provide the first evidence
that hemopexin is overexpressed in di-
abetic eye. Furthermore, we have shown
that hemopexin leads to the disruption
of RPE cells, thus increasing permeabil-
ity, and that this effect is prevented by
dexamethasone.
Hemopexin is probably the primary
specific carrier of plasma heme, having
the highest binding affinity for heme
(13,14). Hemopexin is expressed mainly
in the liver but also in the central nervous
system and peripheral nervous system
(13). In humans, expression of hemo-
pexin has been previously reported in
neuroretina and glial cell (15,16). In the
current study, we have found that hemo-
pexin is also expressed in RPE. Further-
more, we have found that RPE is the part
of the retina with the highest expression
of hemopexin and is the main contributor
to the increase of hemopexin that occurs
in DME. At this point, a double-edged
sword action of hemopexin at the retinal
level could be postulated. Thus, under
physiological conditions hemopexin
could play a protective role against the
toxic effects of iron, but its overexpres-
sion induced by diabetes could favor the
DME.
The reason why hemopexin is over-
expressed in the retina of diabetic patients
with DME is beyond the scope of the
present article. However, it should be
noted that hemopexin belongs to the
acute-phase proteins whose expression
can be induced by various cytokines in a
context of inflammatory processes (17).
Interleukin (IL)-1b, IL-6, IL-8, and tumor
necrosis factor-a have been found to be
elevated in the vitreous fluid of diabetic
patients (18–21), and it has also been
demonstrated that these proinflammatory
cytokines can stimulate hemopexin pro-
duction (8,17). In addition, proinflamm-
tory cytokines play an essential role in the
development of DME (22). Therefore,
proinflammatory cytokines could be the
reason why hemopexin is upregulated in
the retinas from diabetic patients with
DME. Furthermore, high hemopexin lev-
els could be a mechanism by which pro-
inflammatory cytokines lead to BRB
disruption and in turn to DME.
In this study, we provide the first
evidence that hemopexin is able to impair
the sealing function of RPE, thus leading
to an increase of permeability. Notably,
this effect was observed using a hemo-
pexin concentration within the range
found in the vitreous fluid from patients
with DME. In addition, we have provided
evidence that hemopexin induces hyper-
permeability in RPE cells but not in
BRECs. This different behavior of hemo-
pexin is similar to that described in the
kidney. In the renal glomerulus, hemo-
pexin causes increased permeability by
injuring podocytes, which are cells of
epithelial origin such as the RPE, but
does not affect endothelial cells (23). Al-
though it is generally assumed that the
disruption of the inner BRB is the main
cause of DME, there is growing evidence
that the disruption of the outer limiting
membrane and RPE significantly contrib-
utes to the pathogenesis of DME (24–29).
Therefore, it could be postulated that any
treatment addressed to block hemopexin
action, although limited to the outer BRB,
would be effective in preventing or arrest-
ing DME. However, specific studies on
this issue are needed.
The only known receptor for the
heme-hemopexin complex is the scaven-
ger receptor LRP-1, which is expressed in
most cell types (30–32). LRP-1, a member
of the LDL receptor superfamily, is well-
known for its classical role in scavenging
chylomicron remnants in the liver
(32,33). Subsequent studies, however,
have demonstrated that LPR1 also acts
as a multifunctional scavenging receptor
by transporting a variety of ligands in-
cluding proteases into endosomes in the
cells. We have found that LRP1 expres-
sion was higher in RPE that in the neuro-
retina, but there were no significant
differences between patients and control
subjects. Given that LPR1 might bind to
several ligands, its primary role in retinal
physiopathology is still far from being un-
derstood. However, our finding that the
RPE was the part of the retina with higher
expression of both hemopexin and LPR1
suggests an autocrine/paracrine action.
Finally, we found that dexametha-
sone significantly inhibited hemopexin-
induced leakage in RPE cells. Intravitreous
steroidal anti-inflammatory drugs are
currently used for the treatment of DME
(34–37). Apart from their anti-inflammatory
properties, it has been shown that one
important mechanism accounting for the
effectiveness of intravitreous steroidal
drugs is the inhibition of both VEGF
synthesis and downstream receptor
signaling (36,38). The inhibition of
Figure 3dResults of 70 kDa dextran permeability in ARPE-19 cells cultured under 25 mmol/L
D-glucose in the different conditions examined. The vertical axis is the concentration of dextran.
Dextran permeability was measured at 3, 30, 60, and 90 min. Empty bars, control condition
(25 mmol/L D-glucose); black bars, hemopexin (50 mg/mL); striped bars, dexamethasone
(1 mmol/L); gray bars, hemopexin (50 mg/mL) after dexamethasone (1 mmol/L). Results are
expressed as means; n = 4. *P, 0.05 in comparison with hemopexin treatment. FITC, fluorescein
isothiocyanate.
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hemopexin-induced permeability detected
in the current study represents an ad-
ditional mechanism accounting for the
beneficial effects of corticosteroids on
DME.
In conclusion, hemopexin is overex-
pressed in the retina of diabetic patients
with DME and induces outer BRB dis-
ruption. This effect is abrogated by dexa-
methasone. Our findings suggest that
hemopexin can be considered a new can-
didate in the pathogenesis of DME and a
new therapeutic target.
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